Table 1 Clinical characteristics of tumor cohorts.
From: IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis
No. of tumors (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
RNA-seq (test cohort) | In-house tissue microarray (TMA I) | Commercial tissue microarray (TMA II) | ||||||||
ATC | PTC | FTC | ATC | PDTC | PTC | FTC | ATC | PTC | FTC | |
Total | 10 | 6 | 6 | 20 | 18 | 82 | 29 | 6 | 43 | 20 |
Sex | ||||||||||
Female | 7 (70) | 3 (50) | 4 (66.7) | 10 (50) | 10 (55.6) | 44 (53.7) | 11 (37.9) | 4 (66.7) | 37 (86.1) | 14 (70) |
Male | 3 (30) | 3 (50) | 2 (33.3) | 10 (50) | 8 (44.4) | 38 (46.3) | 18 (62.1) | 2 (33.3) | 6 (13.9) | 6 (30) |
Median age, years (range) | 68.5 (48–81) | 50 (23–81) | 55.5 (41–79) | 67 (33–89) | 70 (27–83) | 47 (7–90) | 63 (17–89) | 55.5 (30–86) | 40 (18–76) | 54.5 (20–77) |
UICC stage | ||||||||||
I | 0 | 1 (16.7) | 1 (16.7) | 0 | 2 (11.1) | 49 (59.8) | 10 (34.5) | 0 | 23 (53.5) | 4 (20) |
II | 0 | 2 (33.3) | 1 (16.7) | 0 | 1 (5.6) | 6 (7.3) | 4 (13.8) | 0 | 13 (30.2) | 4 (20) |
III | 0 | 2 (33.3) | 4 (66.7) | 0 | 6 (33.3) | 13 (15.9) | 6 (20.7) | 0 | 7 (16.3) | 11 (55) |
IV | 10 (100) | 1 (16.7) | 0 | 13 (65) | 9 (50) | 13 (15.9) | 1 (3.4) | 6 (100) | 0 | 1 (5) |
nd | 0 | 0 | 0 | 7 (35) | 0 | 1 (1.2) | 8 (27.6) | 0 | 0 | 0 |
